Galapagos and Calchan collaborate on osteoarthritis research, £2.4 million grant awarded by Innovate UK
(Thomson Reuters ONE) -
Mechelen, Belgium and Cambridge, UK, 27 October 2014: Galapagos NV (Euronext:
GLPG), a clinical stage biotech company focused on developing novel mode of
action medicines, and Calchan Limited, a UK company focused on the development
of novel medicines based on calcium ion channel modulators, today announce that
they have entered into a research collaboration in the area of osteoarthritis
pain.
Calchan has been awarded a £2.4 million grant from Innovate UK, the UK's
innovation agency, Biomedical Catalyst Early Stage Round 2to discover and
develop compounds against a novel target for osteoarthritic pain. Calchan and
Galapagos will collaborate in identifying pre-clinical candidates.
Subsequently, Calchan and Galapagos may jointly progress the assets further into
the clinic. Further financial details remain undisclosed.
Brenda Reynolds, Director of Calchan, commented: "We are delighted to have
formed this research alliance with Galapagos and to have received this grant
from Innovate UK. This is our second via this competitive process, and it
provides further recognition of our leading expertise in the discovery and
development of novel pain drug candidates. This new project will combine our
capabilities and expertise in the shared aim of alleviating pain and suffering
in osteoarthritic patients."
Onno van de Stolpe, Chief Executive Officer of Galapagos, commented: "Pain in
osteoarthritis remains a major unmet medical need. This alliance with Calchan
is based on the deep expertise of Galapagos in drug discovery, and complements
our longstanding research efforts in osteoarthritis. Supported by the
Biomedical Catalyst Early Stage Round 2 grant, we look forward to collaborating
with Calchan to bring a new class of osteoarthritis pain medicines to the
clinic."
About Calchan
As part of a restructuring of Convergence Pharmaceuticals in 2011, certain
molecules in development were transferred into Calchan, a sister company, in
which the proprietary rights are held. Calchan is developing its own portfolio
of calcium ion channel modulators and has two Phase II clinical studies in
progress in post-herpetic neuralgia and painful diabetic neuropathy. It has
historically contracted Convergence Pharmaceuticals and other CROs to undertake
certain research and development activities on its behalf.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a pipeline comprising three Phase 2 studies, two Phase 1 studies, five pre-
clinical, and 20 discovery small-molecule and antibody programs in cystic
fibrosis, inflammation, antibiotics and metabolic disease. In the field of
inflammation, AbbVie and Galapagos signed an agreement for the development and
commercialization of GLPG0634. GLPG0634 is an orally-available, selective
inhibitor of JAK1 for the treatment of rheumatoid arthritis and other
inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in
Crohn's disease. Galapagos has another selective JAK1 inhibitor, GSK2586184
(formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). AbbVie and
Galapagos signed an agreement in cystic fibrosis to develop and commercialize
molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is
expected to start Phase 1 in 2014. Galapagos also expects to nominate a pre-
clinical candidate corrector before year end 2014. The Galapagos Group,
including fee-for-service subsidiary Fidelta, has around 400 employees,
operating from its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. Further information at: www.glpg.com
About Innovate UK - the UK's innovation agency
Innovate UK is the new name for the Technology Strategy Board - the UK's
innovation agency. Taking a new idea to market is a challenge. Innovate UK
funds, supports and connects innovative businesses through a unique mix of
people and programmes to accelerate sustainable economic growth. For further
information visit www.innovateuk.org
Catalysts are run jointly by Innovate UK and the Research Councils. A Catalyst
is a form of research and development funding which focuses on a specific
priority area and aims to help take projects from research to as close to
commercial viability as possible. The Catalyst model supports projects in
priority areas where the UK research base has a leading position and where there
is clear commercial potential. Current Catalysts include: Biomedical Catalyst,
Agri-tech Catalyst and the Industrial Biotechnology Catalyst. For more details
please visit: www.innovateuk.org/-/catalysts
For more information about Galapagos, please contact:
Elizabeth Goodwin, T: +31 6 2291 6240
Head of Corporate Communications & IR E: ir(at)glpg.com
For more information about Calchan, please contact:
Calchan
Brenda Reynolds, Director T: +44 (0)1223 755 501
E: info(at)convergencepharma.com
Consilium Strategic Communications
Mary-Jane Elliott/ Amber Bielecka/ Matthew T: +44 (0)20 3709 5700
Neal/ Lindsey Neville E: convergence(at)consilium-comms.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1865902]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="GLENMARK Retains CONTACT FINANCIAL Corp. For Investor RelationsDatum: 27.10.2014 - 07:31 Uhr
Sprache: Deutsch
News-ID 346960
Anzahl Zeichen: 7885
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 225 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos and Calchan collaborate on osteoarthritis research, £2.4 million grant awarded by Innovate UK"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
